⌕
Ascendis Pharma · ASND · Nasdaq
Tenet 53 · Mixed
Compare
$271.73−1.33%At closeTenet 53 · Mixed
$271.73−3.66 (−1.33%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Ascendis Pharma (ASND) Stock

Ascendis Pharma (ASND) closed at $271.73 on Nov 16, 2026; its Tenet Score is 53 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$271.73
Nov 16, 2026
Market cap
$16.8B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
188.08 – 282.15
low → high · as of close, Nov 16, 2026
Tenet Score
53/100
Mixed · 340 Healthcare peers

Industry: Drugs

Ascendis Pharma A/S scores 53/100. Mixed. Strongest on financial health and growth, value is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
53/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
4
Quality
51
Health
83
Growth
74

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthBGrowthBMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
19.9×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−18.9%
before interest and tax
Net margin
−31.7%
fiscal year to Dec 31, 2025
Current ratio
10.65
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with grow…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 92 US ETFs · top wrappers by weightSee all ETFs holding ASND →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Ascendis Pharma in?

Ascendis Pharma is in the Healthcare sector and the Drugs industry.

What is Ascendis Pharma's Tenet Score?

Ascendis Pharma's Tenet Score is 53 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.